Delmaine Donson
- Alvotech (NASDAQ:ALVO) and Fuji Pharma said they are expanding their exclusive commercialization partnership covering Japan by adding a new undisclosed biosimilar candidate.
- The partnership agreement was first announced by the companies in November 2018, and then extended in December 2020 and February 2022.
- The agreement now covers seven biosimilars, including the new candidate, to be developed and manufactured by Alvotech and commercialized by Fuji in Japan, according to the companies.
- "Just recently, we announced the submission of an application for marketing approval in Japan for the first biosimilar candidate developed under our partnership," said Alvotech Founder, Chairman and CEO Robert Wessman.